GSK expands respiratory pipeline with Aiolos Bio acquisition
Drug Discovery World
JANUARY 10, 2024
AIO-001 was exclusively licensed to Aiolos outside of Greater China by Jiangsu Hengrui Pharmaceuticals. Early studies of AIO-001 have shown initial safety, tolerability, pharmacokinetics, and biological activity in healthy volunteers and asthma patients.
Let's personalize your content